Evidence map›Paper›PMID 36048521›Full record

ArticleClinical infectious diseases : an official publication of the Infectious Diseases Society of America2023

Safety of Dengue Vaccine?

Aravinda de Silva

Abstract readComment
In one paragraph

Article in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Analysis of dengue fever disease in West Africa.Experimental biology and medicine (Maywood, N.J.) · 2023
    Pooled it
  2. Article
  3. Article
  4. The Links Between Dengue Virus, Climate and Climate Change.Current topics in microbiology and immunology · 2026
    Review
  5. Article
  6. Article
  7. Review
  8. Article
  9. Review
  10. Dengue: Update on Clinically Relevant Therapeutic Strategies and Vaccines.Current treatment options in infectious diseases · 2023
    Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

1 author.

Aravinda de SilvaDepartment of Microbiology and Immunology, University of North Carolina School of Medicine, Chapel Hill, North Carolina, USA.ORCID 0000-0003-3317-5950

Funding

T Cell Responses Following DENV Natural Infections and Live-Attenuated Dengue Virus VaccinationP01AI106695 · NIAID · UNIVERSITY OF CALIFORNIA BERKELEY · PI Aravinda M. DeSilva · 2015 to 2026
$34.1M
Molecular Basis of Flavivirus Cross-Neutralization by Human AntibodiesR01AI107731 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI DESILVA, ARAVINDA M. · 2013 to 2022
$5.3M
NIAID NIH HHS P01 AI106695NIAID NIH HHS R01 AI107731
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

DengueDengue VaccinesDengue VirusAntibodies, ViralHumansVaccines, AttenuatedAntibodies, ViralDengue VaccinesVaccines, Attenuated

Identifiers

PMID36048521
PMCPMC10308502

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.